Today it was announced that Avanir Pharmaceuticals (Otsuka) has initiated what they call their TRIAD clinical programs. The clinical trials will utilize AVP-786 for the treatment of agitation in patients with Alzheimer's disease. There will be two parts to the initial TRIAD program, Triad-1 which has been initiated, and Triad-2, which will be initiated in 2015 also. The clinicial trial should last around two years.
TRIAD-1 NCT02442765
Dosing will be (DM/Q) 18/4.9 mg, or 28/4.9 mg over 12 weeks, and enroll 380 patients.
TRIAD-2 NCT02442778
Dosing will be (DM/Q) 28/4.9 mg, over 12 weeks, and enroll 325 patients.
Avanir also announced that the company has received "Fast Track" for this indication, and that AVP-786 used for their phase 2 clinical trial as adjunct for major depression disorder, will complete enrollment by the end of 2015.
Bottom Line:
The TRIAD program that has been announced today, is a big commitment to drug AVP-786, not only for agitation in Alzheimer's, but also adjunct for major depression disorder, residual schizophrenia, and disinhibition syndrome. Thank you for reading.
TRIAD-1 NCT02442765
Dosing will be (DM/Q) 18/4.9 mg, or 28/4.9 mg over 12 weeks, and enroll 380 patients.
TRIAD-2 NCT02442778
Dosing will be (DM/Q) 28/4.9 mg, over 12 weeks, and enroll 325 patients.
Avanir also announced that the company has received "Fast Track" for this indication, and that AVP-786 used for their phase 2 clinical trial as adjunct for major depression disorder, will complete enrollment by the end of 2015.
Bottom Line:
The TRIAD program that has been announced today, is a big commitment to drug AVP-786, not only for agitation in Alzheimer's, but also adjunct for major depression disorder, residual schizophrenia, and disinhibition syndrome. Thank you for reading.
No comments:
Post a Comment